Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00177021
Status:
COMPLETED
Last Update Posted:
2006-11-13
First Post:
2005-09-09
Brief Title:
Aldara for the Treatment of Extensive Alopecia Areata
Sponsor:
Hordinsky Maria K MD
Organization:
University of Minnesota
Study Overview
Official Title:
Aldara for the Treatment of Extensive Alopecia Areata
Status:
COMPLETED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We propose to examine the efficacy and tolerability of Aldara Cream 5 for the treatment of extensive alopecia areata Aldara is a immune-response modifier The drug induces the production of cytokines which are small hormone-like proteins involved in cellular communication during immune responses We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata
Detailed Description:
Ten patients with extensive scalp alopecia areata 95 hair lossof less than 2 years duration will be invited to participate in this study For six months each person will be asked to apply Aldara Cream 5 daily to the right half of the scalp No drug will be applied to the left side Skin biopsies will be taken of the right scalp before and at the completion of the therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None